title: Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens.
abstract: BACKGROUND
  In this multi-institutional prospective study, we aimed to assess the safety and efficacy of nedaplatin plus S-1 (NS) chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma (NPC) when platinum-containing regimens failed.
  
  
  METHODS
  A total of 52 recurrent and metastatic NPC patients who previously received, but failed with platinum-containing chemotherapy, had oral S-1 chemotherapy (twice daily from the first day to the fourteenth day) and nedaplatin (80 mg/ m2, day 1) every 3 weeks. The body surface area (BSA) decided the dose of S-1: 40 mg twice a day when BSA < 1.25 m2; 50 mg twice daily when 1.25 m2⩽ BSA < 1.5 m2; and 60 mg twice daily when BSA ⩾ 1.5 m2.
  
  
  RESULTS
  Treatment was well tolerated. The main hematological adverse event was neutropenia. Five patients (9.6%) had grade 3 neutropenia. Three patients were found with grade 3 anemia (5.8%). One patient was found with grade 3 thrombocytopenia (1.9%). No patient was found with grade 3 or 4 nonhematological toxicity. The rates of complete response, partial response and overall response were 3.8%, 38.5% and 42.3%, respectively. Median time to progression was 6.2 months and median survival was 14.6 months. The rates of 1-year survival and 2-year survival were 63% and 27%, respectively.
  
  
  CONCLUSIONS
  NS chemotherapy provides a satisfactory and safe clinical activity for patients with recurrent and metastatic NPC after platinum-containing chemotherapy failed.
authors.affiliation: Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Province, People's Republic of China.
authors.forename: Pei-Jian
authors.initials: PJ
authors.lastname: Peng
authors.affiliation: Department of Surgical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhu Hai, Guangdong Province, China.
authors.forename: Bao-Jun
authors.initials: BJ
authors.lastname: Lv
authors.affiliation: Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Province, People's Republic of China.
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
authors.forename: Hai
authors.initials: H
authors.lastname: Liao
authors.affiliation: Department of Oncology, the People's Hospital of Zhongshan City, Zhongshan, Guangdong Province, China.
authors.forename: Yu-Meng
authors.initials: YM
authors.lastname: Liu
authors.affiliation: Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Province, People's Republic of China.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Lin
authors.affiliation: Department of Medical Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Guangdong Province, People's Republic of China.
authors.forename: Yun-Yan
authors.initials: YY
authors.lastname: Con
authors.affiliation: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of nasopharyngeal carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, China.
authors.forename: Pei-Yu
authors.initials: PY
authors.lastname: Huang
keywords: S-1; chemotherapy; nasopharyngeal carcinoma; nedaplatin